Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6406303 | 1.00 | HTT (0.46) | HTTSMN1; SMN2ALDH1A1POLBALOX12 | |
| SCHEMBL6403780 | 0.79 | CTSK (0.44) | CTSKTSHR | |
| SCHEMBL6408315 | 0.79 | CYP2C9 (0.48) | SMN1; SMN2ALDH1A1CTSKTSHR | |
| SCHEMBL6406194 | 0.79 | CTSK (0.44) | CTSKTSHR | |
| SCHEMBL6403990 | 0.79 | CYP2C9 (0.48) | SMN1; SMN2ALDH1A1CTSKTSHR | |
| SCHEMBL6405409 | 0.79 | CTSK (0.44) | CTSKTSHR | |
| SCHEMBL6402688 | 0.79 | CYP2C9 (0.48) | SMN1; SMN2ALDH1A1CTSKTSHR | |
| SCHEMBL6402731 | 0.77 | HTT (0.50) | HTTSMN1; SMN2ALDH1A1POLBALOX12 | |
| SCHEMBL6406963 | 0.77 | HTT (0.50) | HTTSMN1; SMN2ALDH1A1POLBALOX12 | |
| SCHEMBL6616469 | 0.77 | HTT (0.50) | HTTSMN1; SMN2ALDH1A1POLBALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | CTSK, CTSE, CTSZ | HTT 3860/4885SMN1; SMN2 4636/4885ALDH1A1 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.